IDEXX Laboratories forward PE IDXX
Share price divided by analysts' consensus earnings for the next twelve months, since 1996.
- Today, Oct 23, 2026
- 35.9×
- 10-year median
- 50.3×
- Against its 10-year history
- 5th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 32.0× to 92.5×
- Peer median
- 26.4×
IDEXX Laboratories' forward PE is 35.9× as of Oct 23, 2026.
That is below its ten-year median of 50.3×, lower than on 95% of days in the last ten years.
Over that time it ranged from 32.0× in Apr 2025 to 92.5× in Sep 2021.
The median for 10 diagnostics and research stocks of a similar size is 26.4×.
Forward PE over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 35.9× | 32.4× | 51.1× |
| 2025 | 49.2× | 32.0× | 53.8× |
| 2024 | 35.5× | 35.3× | 54.0× |
| 2023 | 53.4× | 38.8× | 57.3× |
| 2022 | 44.4× | 36.6× | 72.6× |
| 2021 | 86.9× | 65.1× | 92.5× |
| 2020 | 70.9× | 35.2× | 70.9× |
| 2019 | 56.1× | 42.8× | 65.6× |
| 2018 | 42.4× | 42.2× | 64.1× |
| 2017 | 44.2× | 41.7× | 61.2× |
| 2016 | 47.1× | 34.7× | 48.5× |
| 2015 | 38.2× | 33.0× | 44.7× |
| 2014 | 39.7× | 31.6× | 40.4× |
| 2013 | 31.8× | 25.0× | 32.6× |
| 2012 | 28.8× | 26.9× | 32.5× |
| 2011 | 26.9× | 24.2× | 34.5× |
| 2010 | 30.6× | 25.0× | 33.4× |
| 2009 | 27.6× | 18.7× | 29.9× |
| 2008 | 22.1× | 18.3× | 38.3× |
| 2007 | 35.6× | 27.5× | 38.9× |
Against its peers
Companies in Medical - Diagnostics & Research nearest IDEXX Laboratories' size, closest first, today.
| Company | Forward PE |
|---|---|
| IDXXIDEXX Laboratories | 35.9× |
| WATWaters | 29.2× |
| IQVIQVIA | 20.5× |
| ILMNIllumina | 47.2× |
| AAgilent Technologies | 26.4× |
| MTDMettler-Toledo International | 33.9× |
| DGXQuest Diagnostics | n/m |
| LHLabcorp | 17.4× |
| MEDPMedpace | n/m |
| RVTYRevvity | n/m |
| DHRDanaher | 25.4× |
| Peer median | 26.4× |
Where IDEXX Laboratories ranks
What the forward PE tells you
Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.
Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.
More on IDEXX Laboratories
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.